Several networks recapitulated pathways already targeted by late-stage or approved CKD therapies, serving as internal positive controls (such as the inhibition of C3-related disease by pegcetacoplan, or the inhibition of the PPP3CA-NFAT axis by calcineurin inhibitors Fig 6A)25–27. Here, C3 is linked to chronic kidney disease.